Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.

Financial Strength

10/10

Name	Current	Vs Industry
Cash-To-Debt	36.54
Equity-to-Asset	0.9
Debt-to-Equity	0.02
Debt-to-EBITDA	0.14
Interest Coverage	197.07
Piotroski F-Score	4/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	23.57	Distress Grey Safe
Beneish M-Score	-3.08	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

10/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	17.7
	3-Year EBITDA Growth Rate	-1.2
	3-Year EPS without NRI Growth Rate	-2.7
	3-Year FCF Growth Rate	4.6
	3-Year Book Growth Rate	18.3
	Future 3-5Y EPS without NRI Growth Rate	21.49
	Future 3-5Y Total Revenue Growth Rate	23.8

Momentum Rank

3/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	39.19
	9-Day RSI	38.96
	14-Day RSI	41.62
	6-1 Month Momentum %	3.8
	12-1 Month Momentum %	-25.92

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	13.34
	Quick Ratio	13.32
	Cash Ratio	11.33
	Days Inventory	95.83
	Days Sales Outstanding	106.26

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	Shareholder Yield %	0.26

Profitability Rank

10/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	98.63
	Operating Margin %	32.3
	Net Margin %	26.42
	FCF Margin %	42.52
	ROE %	14.91
	ROA %	13.35
	ROIC %	82.06
	ROC (Joel Greenblatt) %	133.19
	ROCE %	18.65
	Years of Profitability over Past 10-Year	10

GF Value Rank

4/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	29.73
	Forward PE Ratio	25.13
	PE Ratio without NRI	27.42
	Shiller PE Ratio	48.01
	Price-to-Owner-Earnings	23.63
	PEG Ratio	1.05
	PS Ratio	7.85
	PB Ratio	4.06
	Price-to-Tangible-Book	4.07
	Price-to-Free-Cash-Flow	18.49
	Price-to-Operating-Cash-Flow	17.55
	EV-to-EBIT	17.51
	EV-to-Forward-EBIT	16.26
	EV-to-EBITDA	17.51
	EV-to-Forward-EBITDA	14.54
	EV-to-Revenue	6.02
	EV-to-Forward-Revenue	5.13
	EV-to-FCF	14.28
	Price-to-Projected-FCF	1.74
	Price-to-DCF (Earnings Based)	0.72
	Price-to-DCF (FCF Based)	0.49
	Price-to-Median-PS-Value	0.33
	Price-to-Peter-Lynch-Fair-Value	1.1
	Price-to-Graham-Number	2.23
	Price-to-Net-Current-Asset-Value	4.35
	Price-to-Net-Cash	5.24
	Earnings Yield (Greenblatt) %	5.71
	FCF Yield %	5.54
	Forward Rate of Return (Yacktman) %	22.96

GF Value: €565.81

WBO:GMAB

Warning Signs

Warning! GuruFocus detected 1 Severe warning sign with GMAB. Try a 7-Day Free Trial to check it out.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.